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Abstract
Aim To provide comprehensive real-world evidence on societal diabetes-attributable costs in Denmark.
Methods National register data are linked on an individual level through unique central personal registration numbers
in Denmark. All patients in the Danish National Diabetes Register in 2011 (N = 318 729) were included in this study.
Complication status was defined according to data from the Danish National Hospital Register. Diabetes-attributable
costs were calculated as the difference between costs of patients with diabetes and the expected costs given the annual
resource consumption of the diabetes-free population.
Results Societal costs attributable todiabeteswere estimated tobeat least 4.27 billionEURin2011, corresponding to14,349
EUR per patient-year. A twofold higher healthcare resource usage was found for patients with diabetes as compared with the
diabetes-free population. Attributable costs, grouped according to different components, were 732 million EUR for primary
and secondary care services, 153 million EUR for pharmaceutical drugs, 851 million EUR for nursing services, 1.77 billion
EUR in lostproductivity and761 millionEURfor additional costs.A steep increase indiabetes-attributable costswas found for
patientswithmajor complications comparedwith patients without complications across all cost components. For attributable
healthcare costs this increase was estimated to be 6,992 EUR per person-year after controlling for potential confounders.
Conclusions Nearly half of the total costs of patients with diabetes can be attributed directly to their diabetes. The
majority of costs are incurred among patients with major complications pointing to the importance of secondary
preventive efforts among patients with diabetes.
Diabet. Med. 33, 877–885 (2016)
Introduction
Globally, healthcare systems are facing the challenge of an
exponential increase in the prevalence of chronic diseases [1].
This puts a heavy economic burden on society as new
successful but costly treatments lead to an increase in care for
more people as life expectancy increases.
With ~ 371 million people diagnosed globally [2] and
evidence of rapidly increasing prevalence [3–6], diabetes
mellitus is one of the most burdensome chronic diseases.
Diabetes is associated with shorter lifetime, reduced quality of
life and economic burdens on the patient and society as a result
of healthcare, pharmaceutical drugs, nursing, reduced labour
market participation and premature mortality [1,7–10].
We aimed to present new evidence of the relationship
between costs of patients with diabetes, with and without
complications, compared with the diabetes-free population
based on data from all relevant national registers in Denmark
[11]. Categorizing patients according to their complication
progression into no complications, minor complications and
major complications, is a novel method intended to inform
decision-makers of a complexproblem in an intuitive and easily
interpretable way. Our results provide an economic rationale
for secondary prevention, which is important to recognizewith
increasing numbers of patients with the chronic condition of
diabetes. Furthermore, the results may contribute to an
awareness among decision-makers regarding the allocation of
budgets which can impede shifts of resources between sectors.
Subjects and methods
Study population
Denmark offers unique opportunities for register-based
research in epidemiology and healthcare [11]. The present
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study is part of a large-scale register-based observational
investigation, the Diabetes Impact Study 2013, investigating
the epidemiological, health economic and socio-economic
aspects of diabetes in Denmark.
The study population was identified from the Danish
National Diabetes Register, adjusted for shortcomings [12],
resulting in a period prevalence of n = 318,729. Person-time
was quantified as number of person-years, defined as 365
person-days (n = 297,378). Patient data were combined with
data from the Danish National Patient Register [13], the
Danish National Prescription Registry [14], the Danish
National Health Service Register [15], the Danish Civil
Registration System [16] and registers at Statistics Denmark.
Municipal statements were used where register data were not
available. Data were linked between registers using the
unique Danish Personal Identification Number, assigned to
each Danish citizen [16].
Analysis
Person-time was stratified by gender and current age (in 5-
year age intervals) into three complication status groups:
no complications, minor complications and major compli-
cations. Documentation on diagnoses and procedural codes
across complication status groups can be found in
Table S1.
The cost of illness framework was applied with a societal
cost perspective, including both direct and indirect costs, but
excluding intangible costs such as psychosocial effects
[10,17]. The analytical time window was the calendar year,
2011. Costs (market values excluding value added tax) [17])
were defined as opportunity costs valued as alternative
forgone use. The following cost components were evaluated
on an individual person level from national register data: 1)
healthcare services in primary and secondary care including
ambulant treatment and emergency room visits; 2) nursing
services in own home/assisted facilities and nurse home visits;
3) pharmaceutical drug consumption; and 4) lost productiv-
ity including lower annual income, absenteeism and prema-
ture mortality, calculated using the human capital approach
[17]. Additional cost components (prevention, education,
psychological assistance, use of self-monitoring of blood
glucose appliances, insulin pumps, medical appliances,
patients’ (and informal care givers’) own time and depreci-
ation of capital) were conservatively estimated from Statistics
Denmark data and the literature. The measurement of cost
components is shown in Table S2.
Attributable costs measure the excess costs of patients with
diabetes’ total healthcare consumption compared with the
annual resource consumption of the diabetes-free popula-
tion, stratified according to gender and age. This approach
means that our attributable cost estimates reflect the cost of
care of patients with diabetes including issues not directly
associated with diabetes, and not solely the cost of diabetes
care. This was applied because earlier studies document that
adding up diabetes-specific diagnoses/services underestimates
the attributable costs compared with a case–control method
[18,19].
For healthcare services, patients with diabetes were com-
pared with the diabetes-free population (n = 5,261,714 in
2011) stratified by gender and 5-year age groups. For
pharmaceutical drugs, nursing and the labour market,
comparisons were made between patients with diabetes and
a matched cohort of the diabetes-free population, consisting
of five control subjects per patient with diabetes, matched
by age, gender and residence at date of diagnosis (n =
1,462,872). As a result of data limitations from source
registers, some cost components were calculated per person
(pharmaceutical drugs, nursing, productivity loss) and some
per person-years (healthcare costs). In calculations across the
different sectors, person-years were applied.
Direct associations between cost components and compli-
cation status groups were explored in a multivariate linear
regression analysis, controlling for potential confounders
(gender, age, highest attained education level, ethnicity, year
of death and region of residence). The dependent variables
were: total and attributable healthcare cost (EUR per person-
years) in primary and secondary care; total net pharmaceu-
tical drug costs; and total costs for home nursing (EUR per
year) in 2011, defined per group according to the indepen-
dent variables. The definitions of these variables are given in
Table S3. T-tests were performed and the significance valued
at the 1% level.
Costs were further analysed according to first ascertain-
ment source in the Danish National Diabetes Register as we
have previously seen that up to 20% of registrants in the
Danish National Diabetes Register are included only as a
result of frequent blood glucose measurements and may not
have diabetes [12].
What’s new?
• Real-world evidence on the attributable costs of
diabetes is calculated from individual register data
and categorized according to complication progression.
• The study shows evidence of twofold higher healthcare
resource usage in patients with diabetes compared with
the diabetes-free population.
• The societal diabetes-attributable costs of diabetes in
Denmark 2011 were estimated to be ~ 4.27 billion
EUR, corresponding to 14,349 EUR per patient year.
• Nearly 60% of diabetes-attributable costs were
ascribed to the 25% of patients with major complica-
tions.
• Steep gradients of increasing costs with increasing
complications were evidenced across all cost compo-
nents.
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Results
Estimates for total and attributable costs and costs per
person-year across cost components, gender and complica-
tion status groups are shown in Tables 1–3. Estimates
excluding possible ‘false-positive’ patients are shown in
Tables S4 and S5. All cost estimates are presented in Euro
(EUR).
Healthcare
Total healthcare costs were estimated to be 1.64 billion
Euro, corresponding to 5509 EUR per person-year. On
average, a patient with diabetes consumed approximately
twice the healthcare resources compared with a diabetes-
free person (1.2, 1.8 and 2.8 times the healthcare resource
use of a diabetes-free person for patients with no, minor
or major complications, respectively) with higher gradi-
ents found among younger patients as compared with the
elderly, among male patients as compared with female
patients, and for secondary care as compared with
primary care. A patient going from no complications to
minor or major complications incurred increased health-
care costs of 1782 and 7534 EUR per person-year,
respectively, even after controlling for potential con-
founders (Table S6).
The total attributable healthcare costs of diabetes were
estimated to be 732 million EUR, divided between the no
complication, minor complication and major complication
groups as follows: 93, 147 and 492 million EUR, respec-
tively. The greatest absolute cost burden was observed in the
age group of 60–74 years, mainly because of the sheer
volume of patients in these age groups.
Average attributable costs per person-year for healthcare
were 2460 EUR (2,128 EUR for women and 2,772 EUR for
men). The costs for patients with minor complications were
4.5 times higher and for patients with major complications
12 times higher than for patients without complications.
Patients with major complications, representing 25% of all
patients, consumed almost 50% of total healthcare
resources. Differences in attributable healthcare costs
between a patient with no complications and a patient with
minor or major complications of 1617 and 7388 EUR per
person-year, respectively, were found, after controlling for
potential confounders (Table S7).
Observed patterns in healthcare resource consumption
are shown in Fig. 1 and may be summarized as follows:
1) gradients between complication status groups were
especially marked for secondary care, where the largest
costs also lay; 2) men consumed more resources in all
secondary care services than women, whereas the oppo-
site was true for primary care; and 3) attributable cost
per person-year decreased with age, mainly as a result of
the diabetes-free population experiencing an increase in
cost with age.
Pharmaceutical drugs
Pharmaceutical drug consumption amounted to 256 million
EUR in 2011, corresponding to 860 EUR per person.
Differences in the costs between no complications and minor
and major complications, respectively, were 257 and 329
EUR per year, after controlling for potential confounders
(Table S8). The pharmaceutical drug consumption of
patients with diabetes was 2.5 times higher than that of the
diabetes-free population: 153 million Euro were found to be
attributable to diabetes. Attributable costs per person-year
were 516 EUR (476 EUR for women and 553 EUR for men),
and were 310, 750 and 788 EUR per person-year for the no
complication, minor complication and major complication
groups, respectively. This shows a significant increase in
pharmaceutical drug costs when patients progressed from
uncomplicated diabetes to minor complications, whereas
later progression to major complications did not impose a
marked increase. For women, the increase from minor to
major complications was 2% and for men 10%. The higher
attributable costs among men were the result of differences in
pharmaceutical drug consumption between genders in the
control group, whereas consumption was approximately
equal for each gender among patients with diabetes.
Attributable costs were highest among the young, and
declined with age (Fig. 2). This pattern is mainly the result of
patients with diabetes having more or less the same
pharmaceutical drug consumption across age groups,
whereas there was increasing consumption with age among
the control subjects.
Nursing
Costs for nursing for patients with diabetes in 2011
amounted to 1.91 billion EUR, corresponding to 6,433
EUR per person. Total attributable nursing costs amounted
to 851 million corresponding to 2,863 EUR per person-year
(3,675 EUR for women and 2,098 EUR for men). When the
attributable costs were divided between the no complication,
minor complication and major complication groups, the
costs were 268, 2,386 and 8,970 EUR, respectively, per
patient. Attributable costs per patient hence increased 33-
fold when patients progressed from uncomplicated diabetes
to diabetes with major complications.
The probability of living in a nursing home for patients with
diabetes was 45% greater compared with the matched
diabetes-free population. For men (in particular those aged
≥ 75 years) negative attributable costswere evidenced, reflect-
ing that men in these older age groups, who have no
complications, use fewer nursing resources than aged-matched
men in the diabetes-free population. Patients with diabetes
received on average 50% more home nursing visits than the
matched diabetes-free population. The difference in total costs
for home nursing between patients with no complications and
those with minor and major complications were estimated to
ª 2015 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. 879
Research article DIABETICMedicine
Table 1 Total diabetes resource use (total costs) and costs per person-year for the entire diabetes population according to complication status and
gender
Cost item
Total costs (EUR) Total cost per person-years (EUR)
ALL C0 C1 C2 ALL C0 C1 C2
Healthcare costs 1,638,237,935 553,933,413 319,439,149 764,865,373 5,509 3,361 5,508 10,257
Women 741,592,485 302,682,783 139,460,753 299,448,949 5,140 3,445 5,670 9,409
Men 896,645,450 251,250,630 179,978,396 465,416,424 5,857 3,265 5,388 10,889
Primary care 221,176,905 110,599,788 42,068,988 68,508,128 744 671 725 919
Women 113,618,643 63,234,638 19,779,391 30,604,615 787 720 804 962
Men 107,558,262 47,365,151 22,289,598 37,903,514 703 616 667 887
Secondary care 1,417,061,030 443,333,624 277,370,161 696,357,244 4,765 2,690 4,782 9,339
Women 627,973,841 239,448,145 119,681,362 268,844,335 4,352 2,725 4,866 8,447
Men 789,087,188 203,885,480 157,688,799 427,512,910 5,154 2,650 4,721 10,002
Pharmaceutical drug costs 255,799,680 102,638,292 62,354,493 90,806,895 860 623 1,075 1,218
Women 124,231,968 56,257,489 28,124,315 39,850,163 861 640 1,143 1,252
Men 131,567,712 46,380,803 34,230,178 50,956,732 859 603 1,025 1,192
Nursing costs 1,913,057,725 486,635,500 319,986,457 1,106,435,768 6,433 2,953 5,517 14,838
Women 1,181,279,919 347,648,931 197,983,759 635,647,229 8,187 3,957 8,050 19,973
Men 731,777,784 138,986,589 122,002,705 470,788,491 4,780 1,806 3,652 11,015
Nursing home 850,952,193 211,354,084 128,233,596 511,364,513 2,862 1,282 2,211 6,858
Women 537,556,556 151,368,523 82,046,366 304,141,667 3,726 1,723 3,336 9,556
Men 313,395,637 59,985,561 46,187,229 207,222,847 2,047 780 1,383 4,848
Nursing in own home 682,300,980 207,788,535 123,110,097 351,402,347 2,294 1,261 2,123 4,713
Women 421,328,648 149,028,783 75,136,381 197,163,484 2,920 1,696 3,055 6,195
Men 260,972,332 58,759,753 47,973,716 154,238,863 1,705 764 1,436 3,609
Home nurse in own home 379,804,552 67,492,881 68,642,764 243,668,907 1,277 410 1,183 3,268
Women 222,394,715 47,251,626 40,801,011 134,342,079 1,541 538 1,659 4,221
Men 157,409,815 20,241,275 27,841,759 109,326,781 1,028 263 833 2,558
Productivity loss 1,770,021,767 584,202,697 360,442,062 825,377,008 5,952 3,545 6,214 11,069
Women 550,569,259 245,373,990 101,862,861 203,332,408 3,816 2,793 4,142 6,389
Men 1,219,452,507 338,828,707 258,579,201 622,044,600 7,965 4,403 7,741 14,553
Lost income 912,272,022 413,992,645 184,680,345 313,599,033 3,068 2,512 3,184 4,206
Women 317,068,466 190,042,378 47,083,003 79,943,085 2,198 2,163 1,914 2,512
Men 595,203,557 223,950,267 137,597,342 233,655,947 3,888 2,910 4,119 5,467
Lost productivity in 2011 as a
result of premature mortality
32,477,477 3,584,403 5,659,401 23,233,674 109 22 98 312
Women 8,209,904 884,182 1,901,945 5,423,777 57 10 77 170
Men 24,267,574 2,700,221 3,757,456 17,809,896 159 35 112 417
Lost productivity in 2011 as a
result of premature deaths
before 2011
723,048,722 122,775,598 144,419,340 455,853,784 2,431 745 2,490 6,113
Women 187,784,170 35,195,124 44,329,134 108,259,911 1,302 401 1,802 3,402
Men 535,264,552 87,580,474 100,090,205 347,593,872 3,496 1,138 2,996 8,132
Absence 102,223,545 43,850,051 25,682,976 32,690,518 344 266 443 438
Women 37,506,720 19,252,307 8,548,779 9,705,634 260 219 348 305
Men 64,716,826 24,597,745 17,134,197 22,984,884 423 320 513 538
Total additional costs 1,096,979,996 285,846,918 193,084,112 618,048,966 3,689 1,734 3,329 8,288
Women 499,242,465 152,580,215 81,802,942 264,859,308 3,460 1,737 3,326 8,322
Men 597,737,531 133,266,704 111,281,170 353,189,657 3,904 1,732 3,331 8,263
Education, prevention,
psychological assistance etc.
23,510,431 13,124,212 4,710,462 5,675,757 79 80 81 76
Women 11,433,432 7,005,481 1,995,657 2,432,294 79 80 81 76
Men 12,076,999 6,118,731 2,714,805 3,243,462 79 80 81 76
SMBG and pumps 66,392,321 38,767,809 13,283,599 14,340,912 223 235 229 192
Women 32,467,058 20,693,596 5,627,794 6,145,668 225 236 229 193
Men 33,925,263 18,074,213 7,655,806 8,195,243 222 235 229 192
Medical appliances 57,486,656 0 0 57,486,656 193 0 0 771
Women 24,635,388 0 0 24,635,388 171 0 0 774
Men 32,851,268 0 0 32,851,268 215 0 0 769
Patients’ and informal care
givers’ time
345,542,010 183,886,084 66,482,029 95,173,897 1,162 1,116 1,146 1,276
Women 167,107,269 98,155,258 28,166,096 40,785,915 1,158 1,117 1,145 1,282
Men 178,434,741 85,730,825 38,315,933 54,387,982 1,166 1,114 1,147 1,272
Depreciation 604,048,579 50,068,814 108,608,022 445,371,743 2,031 304 1,873 5,973
Women 263,599,318 26,725,880 46,013,396 190,860,043 1,827 304 1,871 ½5,997
Men 340,449,260 23,342,934 62,594,626 254,511,701 2,224 303 1,874 5,955
Total for all cost items 6,674,097,103 2,013,256,821 1,255,306,273 3,405,534,010 22,443 12,216 21,643 45,670
Women 3,096,916,097 1,104,543,408 549,234,630 1,443,138,059 21,465 12,572 22,331 45,345
Men 3,577,180,985 908,713,433 706,071,649 1,962,395,903 23,365 11,809 21,137 45,912
C0, no complications; C1, minor complications; C2, major complications; SMBG, self-monitoring of blood glucose.
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Table 2 Diabetes attributable costs and attributable costs per person-year for the diabetes population according to complication status and gender
Cost item
Total attributable cost (EUR)
Total attributable cost per person-
year (EUR)
ALL C0 C1 C2 ALL C0 C1 C2
Healthcare costs 731,520,509 93,151,921 146,557,644 491,810,944 2,460 565 2,527 6,595
Women 307,076,026 56,324,754 65,757,805 184,993,467 2,128 641 2,674 5,813
Men 424,444,483 36,827,167 80,799,839 306,817,477 2,772 479 2,419 7,178
Primary care 23,775,938 8,071,606 4,630,869 11,073,463 80 49 80 149
Women 9,466,709 3,358,214 2,032,360 4,076,136 66 38 83 128
Men 14,309,229 4,713,392 2,598,509 6,997,327 93 61 78 164
Secondary care 707,744,571 85,080,316 141,926,775 480,737,481 2,380 516 2,447 6,447
Women 297,609,317 52,966,541 63,725,445 180,917,331 2,063 603 2,591 5,685
Men 410,135,255 32,113,775 78,201,329 299,820,150 2,679 417 2,341 7,015
Pharmaceutical drug costs 153,372,738 51,151,437 43,493,499 58,727,802 516 310 750 788
Women 68,729,716 25,830,792 18,958,706 23,940,218 476 294 771 752
Men 84,643,022 25,320,645 24,534,793 34,787,584 553 329 734 814
Nursing costs 851,426,972 44,157,419 138,412,494 668,857,059 2,863 268 2,386 8,970
Women 530,191,480 55,119,865 94,574,667 380,496,948 3,675 627 3,845 11,956
Men 321,235,491 -10,962,446 43,837,827 288,360,111 2,098 -142 1,312 6,746
Nursing home 271,179,210 -22,733,872 29,375,665 264,537,417 912 -138 506 3,548
Women 214,979,658 8,249,313 31,006,921 175,723,425 1,490 94 1,261 5,521
Men 56,199,552 -30,983,185 -1,631,255 88,813,992 367 -403 -49 2,078
Nursing in own home 307,899,167 47,914,035 59,025,923 200,959,210 1,035 291 1,018 2,695
Women 180,996,612 39,487,891 36,882,579 104,626,142 1,254 449 1,500 3,287
Men 126,902,555 8,426,144 22,143,344 96,333,067 829 110 663 2,254
Home nurse in own home 272,348,594 18,977,256 50,010,906 203,360,433 916 115 862 2,727
Women 134,215,210 7,382,661 26,685,167 100,147,381 930 84 1,085 3,147
Men 138,133,384 11,594,594 23,325,738 103,213,051 902 151 698 2,415
Productivity loss 1,770,021,767 584,202,697 360,442,062 825,377,008 5,952 3,545 6,214 11,069
Women 550,569,259 245,373,990 101,862,861 203,332,408 3,816 2,793 4,142 6,389
Men 1,219,452,507 338,828,707 258,579,201 622,044,600 7,965 4,403 7,741 14,553
Lost income 912,272,022 413,992,645 184,680,345 313,599,033 3,068 2,512 3,184 4,206
Women 317,068,466 190,042,378 47,083,003 79,943,085 2,198 2,163 1,914 2,512
Men 595,203,557 223,950,267 137,597,342 233,655,947 3,888 2,910 4,119 5,467
Lost productivity in 2011 due to
premature mortality
32,477,477 3,584,403 5,659,401 23,233,674 109 22 98 312
Women 8,209,904 884,182 1,901,945 5,423,777 57 10 77 170
Men 24,267,574 2,700,221 3,757,456 17,809,896 159 35 112 417
Lost productivity in 2011 due to
premature deaths before 2011
723,048,722 122,775,598 144,419,340 455,853,784 2,431 745 2,490 6,113
Women 187,784,170 35,195,124 44,329,134 108,259,911 1,302 401 1,802 3,402
Men 535,264,552 87,580,474 100,090,205 347,593,872 3,496 1,138 2,996 8,132
Absence 102,223,545 43,850,051 25,682,976 32,690,518 344 266 443 438
Women 37,506,720 19,252,307 8,548,779 9,705,634 260 219 348 305
Men 64,716,826 24,597,745 17,134,197 22,984,884 423 320 513 538
Total additional costs 760,778,770 257,979,629 132,635,083 370,164,058 2,558 1,565 2,287 4,964
Women 352,528,414 137,705,130 56,192,816 158,630,468 2,443 1,567 2,285 4,984
Men 408,250,356 120,274,499 76,442,267 211,533,590 2,667 1,563 2,288 4,949
Education, prevention,
psychological assistance etc.
23,510,431 13,124,212 4,710,462 5,675,757 79 80 81 76
Women 11,433,432 7,005,481 1,995,657 2,432,294 79 80 81 76
Men 12,076,999 6,118,731 2,714,805 3,243,462 79 80 81 76
SMBG and pumps 66,392,321 38,767,809 13,283,599 14,340,912 223 235 229 192
Women 32,467,058 20,693,596 5,627,794 6,145,668 225 236 229 193
Men 33,925,263 18,074,213 7,655,806 8,195,243 222 235 229 192
Medical appliances 57,486,656 0 0 57,486,656 193 0 0 771
Women 24,635,388 0 0 24,635,388 171 0 0 774
Men 32,851,268 0 0 32,851,268 215 0 0 769
Patients’ and informal care givers’
time
345,542,010 183,886,084 66,482,029 95,173,897 1,162 1,116 1,146 1,276
Women 167,107,269 98,155,258 28,166,096 40,785,915 1,158 1,117 1,145 1,282
Men 178,434,741 85,730,825 38,315,933 54,387,982 1,166 1,114 1,147 1,272
Depreciation 267,847,352 22,201,524 48,158,993 197,486,835 901 135 830 2,648
Women 116,885,267 11,850,795 20,403,270 84,631,202 810 135 830 2,659
Men 150,962,085 10,350,729 27,755,723 112,855,634 986 135 831 2,640
Total for all cost items 4,267,120,755 1,030,643,103 821,540,781 2,414,936,871 14,349 6,254 14,164 32,386
Women 1,809,094,895 520,354,532 337,346,855 951,393,509 12,539 5,923 13,716 29,894
Men 2,458,025,860 510,288,571 484,193,927 1,463,543,362 16,055 6,631 14,495 34,241
C0, no complications; C1, minor complications; C2, major complications; SMBG, self-monitoring of blood glucose.
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be 299 and 722 EUR per year, respectively, after controlling
for potential confounders (Table S9).
Productivity
In total, the productivity loss amounted to 1.77 billion EUR,
assuming patients with diabetes of working age earned the
same income as the diabetes-free population of the same age,
gender and education level, died at the same age and had not
experienced any excess days of absence attributable to
disease.
Patients with diabetes on average received a lower
annual gross income than matched control subjects after
controlling for education level. This reflected that a higher
percentage of control subjects had jobs requiring high-level
skills, e.g. almost twice as many control subjects held jobs
in managerial positions, whereas patients with diabetes had
a 22% higher unemployment rate and more than twice as
many had retired early (12% compared with 5.4%).
Differences in income level increased with education level
and complication status group, with a maximum annual
difference among patients with major complications
belonging to the highest education level group of 25,229
EUR for men and 24,104 EUR for women in the age
group 55–59 years. The annual difference in mean gross
income according to age in four education level groups is
shown for the no complications group, with men and
women separately in Fig. 3.
Table 3 Total person-years for the entire diabetes population according to complication status and gender
Person years All No complications Minor complications Major complications
Total 297,378 164,809 58,000 74,568
Women 144,281 87,860 24,595 31,826
Men 153,097 76,950 33,405 42,742
FIGURE 1 Total cost of secondary care for the diabetes-free population
(DKnoDM) and patients with diabetes (DM) by complication state
(C0: no, C1: minor and C2: major) for (a) women and (b) men.
FIGURE 2 Diabetes-attributable cost for pharmaceuticals by age,
gender and complication status (C0: no, C1: minor and C2: major).
FIGURE 3 Annual difference in mean gross income according to age
and education level for (a) women and (b) men with no diabetes
complications.
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The total attributable difference in annual gross income
was 912 million EUR. The main share (46%) of the total
productivity loss was attributable to productivity losses
among patients with no complications, because of the
volume of people of working age. Lost productivity in
2011 as a result of premature death from diabetes was
32.4 million EUR calculated from 1,567 premature deaths
corresponding to 52% of the total number of deaths among
patients with diabetes of working age and to 1% of the total
diabetes population in the working age group. Production
foregone in 2011 as a result of premature deaths from
diabetes encountered before 2011 (with production foregone
as a result of the diabetes-attributable deaths until the age of
69 years used as proxy estimate) was estimated to be
723 million EUR, and excess days of absence from work
were estimated to be 102 million EUR in 2011.
Additional costs
Additional costs attributable to diabetes were estimated to be
761 millionEURcorrespondingto2,558EURperperson-year.
Total attributable costs
The total costs of diabetes in Denmark in 2011 were
estimated to be 6.67 billion EUR (22,443 EUR per person-
year), of which 4.27 billion EUR (14,349 EUR per person-
year) were attributable to diabetes. The relative distribution
between cost components is shown in Fig. 4, and the
absolute distribution is shown in the Figure S1.
The total diabetes-attributable costs were divided between
the no complication, minor complication and major compli-
cation groups as follows: 6,254, 14,164 and 32,386 EUR per
person-year, respectively (Fig. 5).
The relative distribution of total attributable costs accord-
ing to complication status and number of person-years
showed that 25% of patients with diabetes consumed nearly
60% of attributable costs (Fig. 6).
Discussion
We found that patients with diabetes consumed approxi-
mately twice the healthcare resources consumed by people
without diabetes. This is less than that documented in earlier
studies [20], indicating that the population with diabetes is
becoming less resource-demanding in the healthcare sector per
person-year, probably as a result of improvements in prognosis
[21,22]. Comparedwith the diabetes-free population, patients
with diabetes incurred their resource use earlier in life, while
later in life they required more specialized care.When patients
with diabetes developed complications, the healthcare and
nursing costs increased markedly. Men in particular used
fewer healthcare services before complications, whereas later
they were more likely than women to progress to major
complications with a need for specialized care. We show a
marked increase in healthcare costs with increasing complica-
tions, even after controlling for relevant confounders. These
findings correspond to those of other studies, which document
major costs related to diabetes complications [23,24]. This
highlights the cost-saving potential of preventing complica-
tions among patients with diabetes and hence the importance
of secondary prevention. Acknowledging thatmore people are
living for longer with diabetes because of prognosis improve-
ments, and that these epidemiological trends cannot be turned
around in the short ormedium term [21,22], the importance of
prevention of expensive complications is highlighted. We
FIGURE 4 Relative distribution of the components of diabetes-
attributable costs.
FIGURE 5 Diabetes attributable costs according to complication status
(C0: no complications; C1: minor complications; C2: major
complications) and gender.
FIGURE 6 Relative distribution of person years (a) and diabetes
attributable costs (b) according to complication status (C0: no
complications; C1: minor complications; C2: major complications).
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found that patients’ morbidity characteristics were the most
important predictors of diabetes-attributable costs. Interest-
ingly, however, the multivariate analysis, showed significant
cost differences according to region of residence, education
level and year of death. This latter finding indicates that the
high attributable costs for younger patients with diabetes
might, to some degree, be attributable to death per se,
irrespective of the cause of death. This methodological issue
should be further investigated. Likewise, underlying associa-
tions between patients’ characteristics and their morbidity
patterns are important to investigate further in order to target
prevention and treatment efforts. These issues will be dealt
with in future work.
Regarding pharmaceutical drug consumption, the greatest
increase in costs was found to be between patients with no
complications and those with minor complications. Clini-
cally, this might be explained by patients with minor
complications being heavily medicated to prevent progres-
sion to major complications. Gender differences point to
women being more proactive in receiving pharmaceutical
drugs earlier in their diabetes (with fewer complications)
than men. Nursing costs were found to be concentrated
among patients with major complications, corresponding to
recent structural changes in Denmark with respect to nursing
services being offered. Patients with diabetes were more
costly than the diabetes-free population, in particular with
respect to visits by a home nurse. Results clearly show
evidence for different labour market patterns among patients
with diabetes compared with the control subjects, and
increasing loss in productivity among patients with diabetes
was seen with an increase in complication levels. When
controlling for education level, it was evident that the main
extent of the income disparities could not be accounted for
by the fact that the diabetes incidence was higher among
people with lower income. We therefore expect the difference
to be attributable to the influence of the ability of the person
with diabetes to work, thus resulting in a lower annual
income. Even though diabetes mainly affects older people in
society, looking at patient volume, we show major costs to
society as well as to the individual in relation to productivity.
The exclusion of patients registered in the Danish National
Diabetes Register solely because of frequent blood glucose
measurements (63,647 person-years) [12] resulted in a
reduction in patients with no complications. Total attribu-
table costs were decreased by 9% (to 3.9 billion EUR), but
attributable cost per person-year increased. We conclude
therefore that estimates for patients with no complications
might be underestimated.
The chosen approach with a 1-year time window has its
limitations, but it allowed a descriptive analysis of the
population in this year [25]. It would be advantageous to
include more years to facilitate analysis of trends over time.
Our data did not allow a distinction between Type 1 and
Type 2 diabetes, which would be advantageous taking the
different aetiology into consideration. Our findings across
age groups indicate high attributable costs among children
and teenagers, reflecting that the diabetes-free population in
these age groups consumes markedly less healthcare, nursing
services and pharmaceutical drugs.
Categorizing patients according to their development of
complications; i.e. no complications, minor complications
and major complications, is a novel method within this field.
We aimed to contribute to this field with an easily under-
standable outline of the cost pattern for a very complex
disease, providing decision-makers with the necessary guid-
ance for future investments in diabetes.
The presented cost distributions by component and by
complication status are presumably not only valid in a
Danish setting but could be transferred to other countries
and chronic diseases.
Based on all available data in Danish national health
registers for all patients with diabetes in 2011, the costs
attributable to diabetes were estimated to be at least
4.27 billion EUR, corresponding to 14,349 EUR per per-
son-year. We show a steep increase in attributable costs for
patients with major complications compared with patients
without complications across all cost components, also when
potential confounders are controlled for. Our results under-
line the universal message of cost increases with increased
complications, providing an economic rationale for sec-
ondary prevention.
Evidence of cost distributions within diabetes can guide
future efforts in specific sectors, or targeted patient groups,
based on expected cost savings.
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